Compounds > astragaloside iii
Page last updated: 2024-12-08

astragaloside iii

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

astragaloside III: from Astragali Radix; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

astragaloside III : A triterpenoid saponin that is cycloastragenol with a 2-O-beta-D-glucopyranosyl-beta-D-xylopyranosyl moiety attached at position 3 via a glycosidic linkage. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID441905
CHEBI ID2897
MeSH IDM0592323

Synonyms (20)

Synonym
astragaloside-iii
astragaloside iii
84687-42-3
C08924
(3beta,6alpha,9beta,16beta,20r,24s)-6,16,25-trihydroxy-20,24-epoxy-9,19-cyclolanostan-3-yl 2-o-beta-d-glucopyranosyl-beta-d-xylopyranoside
CHEBI:2897 ,
CS-3713
astragaloside iii (constituent of astragalus) [dsc]
beta-d-xylopyranoside, (3beta,6alpha,16beta,20r,24s)-20,24-epoxy-6,16,25-trihydroxy-9,19-cyclolanostan-3-yl 2-o-beta-d-glucopyranosyl-
unii-wvp53009fc
wvp53009fc ,
.beta.-d-xylopyranoside, (3.beta.,6.alpha.,16.beta.,20r,24s)-20,24-epoxy-6,16,25-trihydroxy-9,19-cyclolanostan-3-yl 2-o-.beta.-d-glucopyranosyl-
HY-N0434
DTXSID40331663 ,
AKOS030526183
Q27105868
(2s,3r,4s,5s,6r)-2-(((2s,3r,4s,5r)-2-(((2ar,3r,4s,5as,5bs,7s,7ar,9s,11ar,12as)-4,7-dihydroxy-3-((2r,5s)-5-(2-hydroxypropan-2-yl)-2-methyltetrahydrofuran-2-yl)-2a,5a,8,8-tetramethylhexadecahydrocyclopenta[a]cyclopropa[e]phenanthren-9-yl)oxy)-4,5-dihydroxyt
(2s,3r,4s,5s,6r)-2-[(2s,3r,4s,5r)-2-[[(1s,3r,6s,8r,9s,11s,12s,14s,15r,16r)-9,14-dihydroxy-15-[(2r,5s)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethyl-6-pentacyclo[9.7.0.01,3.03,8.012,16]octadecanyl]oxy]-4,5-dihydroxyoxan-3-yl]oxy-6-(hy
astragaloside iii (constituent of astragalus)
dtxcid90282757

Research Excerpts

Overview

Astragaloside III (AS-III) is a triterpenoid saponin contained in Astragali Radix. It has potent anti-inflammatory effects on vascular endothelial cells.

ExcerptReferenceRelevance
"Astragaloside III (AS-III) is a triterpenoid saponin contained in Astragali Radix and has potent anti-inflammatory effects on vascular endothelial cells; however, underlying mechanisms are unclear. "( Astragaloside III activates TACE/ADAM17-dependent anti-inflammatory and growth factor signaling in endothelial cells in a p38-dependent fashion.
Cao, Q; Huang, X; Huo, X; Liu, Q; Pan, Y; Ren, D; Wang, H; Wang, M; Wu, M; Yuan, R; Zhang, L; Zhao, X, 2020)		3.44

Pharmacokinetics

ExcerptReferenceRelevance
" The method was successfully used to investigate the pharmacokinetic profile of AST III after oral (10 mg/kg) and intravenous (1."( Determination of astragaloside III in rat plasma by liquid chromatography-tandem mass spectrometry and its application to a rat pharmacokinetic study.
Gong, M; Li, P; Qiu, F; Wang, M; Zhai, Y, 2016)		0.77
"A rapid and simple ultra-performance liquid chromatography-electrospray ionization-mass spectrometry (UPLC-ESI-MS) method for the determination of astragaloside III was developed and used in a pharmacokinetic and tissue distribution study in rats following the oral administration 95% ethanol extraction of Zhenqi Fuzheng capsules."( Development and Validation of a Rapid and Simple UPLC-ESI-MS Method for Pharmacokinetics and Tissue Distribution of Astragaloside III in Rats.
Chen, XY; Feng, SL; Guo, L; Hu, F; Liu, XH; Yang, YL, )		0.54
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
triterpenoid saponinA terpene glycoside in which the terpene moiety is a triterpenoid.
disaccharide derivativeA carbohydrate derivative that is formally obtained from a disaccharide.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (50.00)24.3611
2020's4 (50.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 15.77

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index15.77 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.62 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index3.00 (0.95)

This Compound (15.77)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
glucose, (beta-d)-isomer
beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.		2.0810D-glucopyranoseepitope;
mouse metabolite
astragaloside a
[no description available]		3.2650
formononetin
[no description available]		2.08104'-methoxyisoflavones;
7-hydroxyisoflavones		phytoestrogen;
plant metabolite
7,3'-dihydroxy-4'-methoxyisoflavone
7,3'-dihydroxy-4'-methoxyisoflavone: isolated from Astragali radix; structure in first source. calycosin : A member of the class of 7-hydroxyisoflavones that is 7-hydroxyisoflavone which is substituted by an additional hydroxy group at the 3' position and a methoxy group at the 4' position.		2.08104'-methoxyisoflavones;
7-hydroxyisoflavones		antioxidant;
metabolite
calycosin-7-o-beta-d-glucopyranoside
calycosin-7-O-beta-D-glucoside: from Radix Astragali. calycosin-7-O-beta-D-glucoside : A glycosyloxyisoflavone that is calycosin substituted by a beta-D-glucopyranosyl residue at position at 7 via a glycosidic linkage.		2.08104'-methoxyisoflavones;
7-hydroxyisoflavones 7-O-beta-D-glucoside;
hydroxyisoflavone;
monosaccharide derivative
beta-escin
[no description available]		3.6680
astragaloside ii
astragaloside II: a potent multidrug resistance (MDR) reversal agent from Astragalus; structure in first source. astragaloside II : A triterpenoid saponin that is cycloastragenol glycosylated at positions 3 and 6 by 2-O-acetyl-beta-D-xylosyl and beta-D-glucosyl residues respectively.		7.8830beta-D-glucoside;
monosaccharide derivative;
oxolanes;
pentacyclic triterpenoid;
triterpenoid saponin		plant metabolite
astragaloside vii
astragaloside VII: from Astragalus trojanus Stev.; structure in first source		2.3110
ConditionIndicatedRelationship StrengthStudiesTrials
Break-Bone Fever
[description not available]		02.3110
Dengue
An acute febrile disease transmitted by the bite of AEDES mosquitoes infected with DENGUE VIRUS. It is self-limiting and characterized by fever, myalgia, headache, and rash. SEVERE DENGUE is a more virulent form of dengue.		07.3110
Rheumatoid Arthritis
[description not available]		02.3110
Arthritis, Rheumatoid
A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.		02.3110
Cirrhosis, Liver
[description not available]		02.1110
Liver Cirrhosis
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.		02.1110
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.1310